Sirtuin Inhibitor

SIRT-IN-5 is a SIRT3 inhibitor, with an IC₅₀ value of 2.88 μM. SIRT-IN-5 can promote the differentiation of multiple myeloma cells, along with an increase in the expression of the differentiation antigen CD49e and human immunoglobulin light chains λ and κ.

Sirtuin-IN-1 (Compound 18) is a SIRT1/2 inhibitor (IC₅₀s: 6.2 μM and 4.2μM for SIRT1 and SIRT2, respectively). Sirtuin-IN-1 induces G1 cell cycle arrest. Sirtuin-IN-1 exhibits potent anti-cancer activity against glioma.

Sirtuin modulator 4 (compound 12) is a sirtuin modulator. Sirtuin modulator 4 shows inhibitory effect to SIRT1 with an EC₅₀ value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.

HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and HSP70, with IC₅₀ of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity.

SIRT1-IN-5 (215) is a NAD-dependent protein deacetylase sirtuin-1 modulator.

SIRT2-IN-14 (Compound 78) is a selectve inhibitor for SIRT2 with an IC₅₀ of 0.196 μM.

Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC₅₀s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity.

Sirt5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sirt5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SIRT-IN-4 is an inhibitor of the NAD+-dependent lysine deacetylase Sirtuin2 (Sirt2) (IC₅₀=0.35 μM). SIRT-IN-4 is a potent Sirt2 deacetylase inhibitor that reduces cell survival and inhibits the migration of prostate cancer cells. SIRT-IN-4 can be used to study Sirt2 in cell cycle regulation, gene expression regulation, etc.

SIRT5 inhibitor 2 (compound 49) is a potent SIRT5 inhibitor with an IC₅₀ value of 2.3 μM. SIRT5 inhibitor 2 has inhibitory activity against the SIRT5-dependent desuccinylation. SIRT5 inhibitor 2 can be used for researching cancer and neurodegenerative diseases.

NCO-90 is a selective SIRT2 inhibitor with an IC₅₀ of 1.0 μM. NCO-90 induces Apoptosis via Caspase activation and mitochondrial superoxide anion production, and also induces Autophagic cell death by increasing LC3-II levels and autophagosome accumulation. NCO-90 exhibits anticancer activity against leukemia. NCO-90 can be used in research related to acute lymphoblastic leukemia and acute myeloid leukemia.

Antileishmanial agent-44 is a histone deacetylase inhibitor targeting Leishmania donovani Sir2, with an IC₅₀ of 0.652 μM against amastigotes. Antileishmanial agent-44 elevates ROS levels to induce oxidative stress, which causes mitochondrial membrane potential depolarization, cytochrome c release, phosphatidylserine externalization and DNA fragmentation, triggers apoptosis-like cell death, and arrests the cell cycle. Antileishmanial agent-44 upregulates the expression of Th1-type cytokines and NO in macrophages, reshapes host immune responses to eliminate intracellular parasites. Antileishmanial agent-44 inhibits parasites in infected golden hamsters in vivo. Antileishmanial agent-44 can be used for the research of visceral leishmaniasis.

ZINC08792355 is a SIRT1 inhibitor and can be used for study of ageing, diabetes, and cancer..

SL010110 is an anti-hyperglycemic agent. SL010110 potently inhibits gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 degradation. SL010110 downregulates the protein level of PEPCK1 without affecting the gene expressions of PEPCK, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. SL010110 significantly improves glucose homeostasis in type 2 diabetic (T2D) mice model. SL010110 can be used for T2D research.

Sirtuin-IN-2 (compound 20) is an inhibitor of Sirtuin5, which is a key target for leukemia and breast cancer.

NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity.

SR94, a SR17 derivative, is a SIRT2 inhibitor that contains an arbitrary 6-member ring and different R2 groups. SR94 is promising for research of cancer, ischemia-reperfusion and neurodegenerative diseases.

SIRT1-IN-7 is a weak inhibitor of SIRT1 with an IC₅₀ > 100 μM. SIRT1-IN-7 can be used in cancer-related research, such as breast cancer research.

HSP70/SIRT2-IN-1 (Compounds 2a) is a dual inhibitor for SIRT2 and HSP70, with IC₅₀ of 17.3±2.0 μM for SIRT2. HSP70/SIRT2-IN-1 has antitumor activity.

Sirt6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirt6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.